Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111539 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

211

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG: Escitalopram
DRUG: Aripiprazole
DRUG: Blinded capsule

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.